Akesobio 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   2 Trials   5 News 
525 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
quavonlimab (MK-1308) / Merck (MSD)
KeyImPaCT, NCT03516981 / 2017-003134-85: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Completed
2
245
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Favezelimab, MK-4280, Lenvatinib, MK-7902, Quavonlimab, MK-1308
Merck Sharp & Dohme LLC
Advanced Non-Small Cell Lung Cancer
06/25
06/25
2019-003956-35: Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 Refractory MEL

Not yet recruiting
1/2
200
Europe
PEMBROLIZUMAB, MK-1308 -process 2 drug product (25 mg/vial), Lenvatinib, MK-3475, MK-1308, E7080/MK-7902, MK-7684, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
MK-1308-001, NCT03179436: Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors

Checkmark Data from MK-1308-001 trial in combination with pembrolizumab in advanced melanoma
Jun 2022 - Jun 2022: Data from MK-1308-001 trial in combination with pembrolizumab in advanced melanoma
Checkmark Data from MK-1308-001 study in combination with quavonlimab for NSCLC
Oct 2020 - Oct 2020: Data from MK-1308-001 study in combination with quavonlimab for NSCLC
Completed
1/2
415
Europe, Canada, Japan, US, RoW
Quavonlimab, MK-1308, Pembrolizumab, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A
Merck Sharp & Dohme LLC
Advanced Solid Tumors
04/24
04/24
KEYMAKER-U02 Substudy 02A, NCT04305041: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Active, not recruiting
1/2
200
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Quavonlimab, MK-1308, Vibostolimab, MK-7684, Lenvatinib, MK-7902, LENVIMA®, ATRA, VESANOID
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
ebronucimab (AK102) / Akesobio
NCT05255094: A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Completed
3
464
RoW
AK102, Placebo
Akeso
Hyperlipidemia
06/22
06/22
NCT05255458: A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Completed
3
122
RoW
AK102, Placebo
Akeso
Hyperlipidemia
01/23
01/23
NCT05260411: A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Completed
3
246
RoW
AK102, Placebo
Akeso
Hyperlipidemia
12/22
12/22
NCT06641388: A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

Not yet recruiting
1
180
RoW
Ebronucimab
Akeso
Healthy Subjects (HS)
04/25
06/25
NCT07043283: A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects

Not yet recruiting
1
204
RoW
Ebronucimab
Akeso
Healthy Subjects
04/26
04/26
Kaitanni (cadonilimab) / Akesobio
ChiCTR2300070963: Prospective, open cohort study of sulfatinib in combination with cadonilimab for first-line treatment of extensive-stage small-cell lung cancer

Not yet recruiting
4
80
 
None ;None ;None ;None
The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, self-finance
Small cell lung cancer
 
 
ChiCTR2200065303: A single-arm, prospective, exploratory clinical study of fruquintinib plus candonilimab in advanced colorectal cancer

Not yet recruiting
4
31
 
fruquintinib plus candonilimab
Nanjing Hospital of Traditional Chinese Medicine; Nanjing Hospital of Traditional Chinese Medicine, Self-financing
colorectal cancer
 
 
ChiCTR2300071201: Exploratory clinical study of candonilimab plus bevacizumab in patients with relapsed diffuse midline glioma

Recruiting
4
30
 
Cardonilizumab combined with bevacizumab was administered every 3 weeks until 1 year or disease progression or unacceptable toxicities, or withdrew consent.
Sanbo Brain Hospital Capital Medical University; Sanbo Brain Hospital Capital Medical University, Akeso Biopharma Co., Ltd.
diffuse midline glioma
 
 
LungCadX, ChiCTR2300071681: A Phase II Clinical Study of Cadonilimab in Combination with Chemotherapy as First-Line Treatment for PD-L1 Negative Advanced Non-Small Cell Lung Cancer

Not yet recruiting
4
54
 
Cadonilimab + chemotherapy (chemotherapy regimen determined by the investigator)
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Shanghai Pulmonary Hospital
Non-Small Cell Lung Cancer
 
 
ChiCTR2400082911: A prospective, single-arm, single-center clinical trial of Cadonilimab combined with radiotherapy in the first-line treatment of advanced malignant melanoma

Not yet recruiting
4
40
 
Cadonilimab combined with radiotherapy
Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Self-funded
advanced malignant melanoma
 
 
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Active, not recruiting
3
610
RoW
AK104, Oxaliplatin, Capecitabine, Placebo
Akeso
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/25
10/25
AK104-IIT-C-M-0020, NCT06566755: Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

Recruiting
3
30
RoW
Cadonilimab (AK104) combined with chemotherapy and bevacizumab
Caigang Liu
Colorectal Cancer
02/26
02/27
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
3
506
RoW
cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo
Akeso
Gastric and Gastroesophageal Junction Adenocarcinoma
11/26
07/27
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting
3
469
RoW
AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib
Akeso
Hepatocellular Carcinoma
10/25
05/26
NCT06542549: Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

Not yet recruiting
3
100
NA
AK104
Anhui Provincial Hospital
Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, Safety
10/27
10/30
NCT06664983: TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
84
RoW
TPC chemotherapy, NAB-paclitaxel, cisplatin, and capecitabine, cadonilimab combined TPC chemotherapy, cadonilimab combined NAB-paclitaxel, cisplatin, and capecitabine
Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
10/25
10/26
AK104-309, NCT06617416: A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Recruiting
3
560
RoW
Cadonilimab (AK104), Sugemalimab
Akeso
NSCLC (Non-small Cell Lung Cancer)
10/26
12/28
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Recruiting
3
418
RoW
Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Akeso Pharmaceuticals, Inc.
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
01/25
01/27
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Recruiting
3
570
RoW
AK104, placebo
Akeso
Hepatocellular Carcinoma
01/26
01/27
NeoCaCRT-III, NCT06832917: Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial

Not yet recruiting
3
238
NA
AK104 plus, Chemo only
Wan He
Rectal Cancer
12/28
12/29
COMPASSION-16, NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Active, not recruiting
3
445
RoW
AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo
Akeso
Cervical Cancer
04/25
12/25
NCT06949033: Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
3
668
RoW
Neoadjuvant cadonilimab combined with perioperative SOX, Neoadjuvant placebo plus perioperative SOX
Zuoyi Jiao
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR, ORR,OS,PFS
12/28
12/30
NCT07023315: A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Not yet recruiting
3
760
RoW
Cadonilimab, SOX chemotherapy
Akeso
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
07/29
07/31
AK104-307, NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not yet recruiting
3
642
RoW
AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel
Akeso
Locally Advanced or Metastatic NSCLC
08/25
11/26
COMPASSION-18, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Active, not recruiting
3
636
RoW
AK104, EBRT, BT, cisplatin, Placebo
Akeso
Locally Advanced Cervical Carcinoma
05/26
05/29
ChiCTR2400087138: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting
3
469
 
Cadonilimab(AK104) + Lenvatinib+ Transarterial Chemoembolization (TACE); Placebo for AK104+ Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE); Cadonilimab(AK104) + Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE)
Zhongda Hospital Southeast University; Zhongda Hospital Southeast University, Akeso Pharma Co., Ltd.
Hepatocellular carcinoma
 
 
NCT05941741: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Active, not recruiting
3
380
RoW
Intensity Modulated Radiation Therapy, IMRT, Chemotherapy, Induction chemotherapy, Concurrent chemotherapy, Gemcitabine, Cisplatin, Immune checkpoint inhibitor, Cadonilimab, AK104, PD-1/CTLA-4 inhibitor, Low-dose radiotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
12/26
12/29
NCT06241599: A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Recruiting
2/3
300
RoW
GP/PFLL+AK104, GP/PFLL+placebo
Sun Yat-sen University
Recurrent or Metastatic Nasopharyngeal Carcinoma
02/26
02/29
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting
2/3
90
RoW
Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection
RemeGen Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/26
12/27
ChiCTR2300076761: Efficacy and Safety of Cadonilimab and COX-2 Inhibitor Combined with Oxaliplatin and Capecitabine (XELOX) in Perioperative Therapy for Locally Advanced Resectable Gastric Adenocarcinoma: A Prospective, Single-Center, Randomized Clinical Trial

Recruiting
2/3
80
 
Cardonilizumab and COX-2 inhibitors combined with capecitabine and oxaliplatin (XELOX) applied in the perioperative period; Capecitabine and oxaliplatin (XELOX) applied in the perioperative period
The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital Sun Yat-sen University, Akeso Pharma Co., Ltd
Gastric cancer
 
 
ChiCTR2300072956: A randomized, controlled, double-blind, multicenter phase II clinical study of PD-1/CTLA-4 dual antibody combined with chemoradiotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma

Not yet recruiting
2/3
64
 
cadonilimab + induction chemotherapy + Concurrent chemoradiotherapy ;placebo + induction chemotherapy + Concurrent chemoradiotherapy
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project
nasopharyngeal carcinoma
 
 
NCT06728631: Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

Active, not recruiting
2
22
RoW
Candonilimab and ATRA, other treatment or observation
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Oral Cavity Cancer, Premalignant Lesion
12/23
12/26
AK104-209, NCT04728321: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Completed
2
32
RoW
AK104 lenvatinib, AK104
Akeso, Akeso Pharmaceuticals, Inc.
Hepatocellular Carcinoma
08/22
08/23
NCT04544644: A Study of Combination Therapy in NSCLC

Not yet recruiting
2
30
NA
AK104+anlotinib
Chinese PLA General Hospital
Non-small Cell Lung Cancer
09/22
09/23
ChiCTR2000035993: A phase II study of AK104 (binding kenetics to PD-1 and CTLA-4) in combination with anlotinib in patients with advanced NSCLC

Not yet recruiting
2
30
 
AK104+anlotinib
Chinese PLA General Hospital; Chinese PLA General Hospital, Charity organization
Non-small cell lung cancer
 
 
NCT04556253: AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Not yet recruiting
2
29
NA
AK104
Peking University
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
10/22
10/23
COMPASSION-13, NCT04868708: A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Completed
2
50
RoW
AK104, Bevacizumab, Paclitaxel, PTX, Cisplatin or Carboplatin, DDP,CBP
Akeso
Recurrent or Metastatic Cervical Cancer
02/24
02/24
AK104-215, NCT05215067: A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting
2
44
RoW
AK104, Docetaxel
Akeso
Advanced Non-small Cell Lung Cancer
06/25
06/26
AK104-214, NCT05227651: AK104 in Neoadjuvant Treatment of Cervical Cancer

Completed
2
14
RoW
AK104
Akeso
Cervical Cancer
09/24
09/24
NCT05886257: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Withdrawn
2
RoW
Candonilimab, Bevacizumab
Shi Ming
Hepatocellular Carcinoma
03/23
03/23
AK104-216, NCT05319431: A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Active, not recruiting
2
60
RoW
AK104, Lenvatinib, TACE
Akeso
Unresectable, Non-metastatic Hepatocellular Carcinoma
08/23
06/25
NCT06383533: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Recruiting
2
28
RoW
Disitamab Vedotin Plus Cadonilimab
Zhejiang Cancer Hospital
Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation
05/25
12/25
GWK2023-001, NCT06335927: HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Recruiting
2
45
RoW
HAIC-GEMOX+Cadonilimab+Regorafenib
Fudan University
Intrahepatic Cholangiocarcinoma
05/25
05/26
NCT06341660: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
30
RoW
cadonilimab
Guangzhou Institute of Respiratory Disease
Non-small Cell Lung Cancer
06/25
07/25
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Recruiting
2
40
RoW
Fruquintinib, Cadonilimab, SBRT
Huazhong University of Science and Technology
Colorectal Cancer
02/26
02/27
LungCadX, NCT06424821: Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Recruiting
2
54
RoW
Cadonilimab, Cadonilimab group
Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
09/24
09/25
AK104-RC48 UC 01, NCT06178601: A Study of RC48-ADC Combined With Cadonilimab(AK104)in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
2
36
RoW
RC48-ADC, AK104
Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Urothelial Carcinoma
09/24
04/26
NCT06331650: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Recruiting
2
30
RoW
cadonilimab
Guangzhou Institute of Respiratory Disease
Non-small Cell Lung Cancer
08/25
10/25
NCT06209294: Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Recruiting
2
30
RoW
AK104, Carboplatin, Nab paclitaxel
Xiaohua Wu
Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery
12/25
12/28
NCT06138496: Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Recruiting
2
43
RoW
Cadonilimab Combined With Lenvatinib
Sun Yat-sen University
Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
08/25
12/25
NCT06455046: Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Recruiting
2
37
RoW
AK104, Cadonilimab, Recombinant Human Adenovirus 5 Injection, Recombinant Human Adenovirus Type 5 Injection
Fujian Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province
Cervical Cancer Recurrent
10/25
10/25
AK104-SCLC-01, NCT06406673: A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Recruiting
2
70
RoW
Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
Henan Cancer Hospital
Extensive Small Cell Lung Cancer
08/24
12/24
NCT06154538: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Recruiting
2
170
RoW
Cadonilimab, 1, FOLFOX regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Colorectal Carcinoma
11/26
11/28
ZF2023-252, NCT06277674: Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Recruiting
2
20
RoW
Cadonilimab plus Pemetrexed and Anlotinib, ICIs in combination with chemotherapy and antiangiogenic therapy
Guangzhou University of Traditional Chinese Medicine, Akeso Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
12/24
06/25
NCT05594914: AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
47
NA
AK104
The First Affiliated Hospital of University of South China
Esophageal Squamous Cell Carcinoma
12/23
12/25
NCT05781958: Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Active, not recruiting
2
64
RoW
Cadonilimab+Gem/Cis
Shen Feng
Intrahepatic Cholangiocarcinoma
12/23
12/24
AK104-IIT-003, NCT05430906: AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Recruiting
2
40
RoW
AK104 - Chemotherapy
Hunan Cancer Hospital
Ovarian Cancer
12/23
01/26
CCGLC-011, NCT06187961: Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting
2
36
RoW
HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Lenvatinib plus cadonilimab, levima plus cadonilimab
Tongji Hospital, Akesobio
Hepatocellular Carcinoma Non-resectable
12/25
06/27
NCT06153368: Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

Not yet recruiting
2
30
RoW
Cadonilimab+mFOLFIRINOX, Cadonilimab+Oxaliplatin+ Irinotecan+ Leucovorin+ 5-fluorouracil
The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer
11/24
11/25
MSI-H/dMMR, NCT05913570: Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III Colorectal Cancer

Not yet recruiting
2
22
RoW
Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody, Neoadjuvant therapy with Cadonilimab
LiuYing
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
12/23
12/23
ChiCTR2200067057: Cadonilimab in combination with TPC chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patient who failed to prior immunotherapy: a prospective, open labeled phase II clinical trial

Completed
2
25
 
cadonilimab in combination with TPC chemotherapy
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, NA
Nasopharyngeal Carcinoma
 
 
NCT05760599: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Recruiting
2
30
RoW
Candonilimab, Bevacizumab
Shi Ming
Hepatocellular Carcinoma
01/24
07/24
NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Recruiting
2
53
RoW
Cadonilimab + bevacizumab + FOLFOX
Fudan University
Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
12/25
12/26
CATPCC-01, NCT06511726: Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting
2
29
RoW
Cadonilimab, AK-104
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Cancer
10/25
10/27
NCT06793813: Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
44
RoW
cadonilimab,bevacizumab,docetaxel
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage IVB Lung Cancer, Non-Squamous
12/25
12/26
AK104-IIT-042, NCT06196775: A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
36
RoW
AK104+AK112
Harbin Medical University
Hepatocellular Carcinoma
01/26
01/27
NCT05926700: Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Recruiting
2
27
RoW
Candonilimab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Soft Tissue Sarcoma
08/24
01/25
AK104-IIT-007, NCT06202313: Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Not yet recruiting
2
128
RoW
Cadonilimab, AK104, Eribulin
Shengjing Hospital
Triple Negative Breast Cancer
12/25
12/28
NCT06251388: A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab(AK104) for Newly Diagnosed Local Advanced Cervical Cancer

Recruiting
2
50
RoW
AK104, Cadonilimab Injection
West China Second University Hospital, Affiliated Hospital of North Sichuan Medical College, The Affiliated Hospital Of Southwest Medical University
Cervical Cancer
05/25
10/26
AK104-IIT-005, NCT05377658: AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Recruiting
2
43
RoW
AK104, Cadonilimab, Albumin-Bound Paclitaxel, Carboplatin
Henan Cancer Hospital
Non-small Cell Lung Cancer
12/24
12/27
NCT05947201: Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
26
RoW
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil, rutine
Weijia Fang, MD, Akeso Pharmaceuticals, Inc.
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
03/24
10/24
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting
2
20
RoW
cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU
Fujian Cancer Hospital
Colorectal Cancer
03/24
03/25
NCT06310473: Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Not yet recruiting
2
30
RoW
Cadonilimab, AK104, Oxaliplatin, Capecitabine
Nanfang Hospital, Southern Medical University
Gastric Cancer, Esophagogastric Junction Cancer
03/25
03/28
NCT06467500: A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy

Recruiting
2
48
RoW
Cadonilimab (AK104)
Xin-Hua Xu
Non-small Cell Lung Cancer
12/26
12/26
EC-CRT-006, NCT06143748: Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer

Recruiting
2
46
RoW
Cadonilimab, AK104, Paclitaxel and cisplatin, taxol, DDP, intensity-modulated radiotherapy, IMRT
Sun Yat-sen University
Esophagus Cancer
12/25
12/27
NCT06215651: Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
Cadonilimab lenvatinib, AK104
Peking Union Medical College Hospital
Cadonilimab and Lenvatinib
01/25
01/27
NCT06280105: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Recruiting
2
40
RoW
Cadonilimab+regorafenib
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Hepatocellular Carcinoma
03/26
03/27
AK104-IIT-014, NCT05522894: AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Not yet recruiting
2
80
NA
AK104, Cadonilimab, Cisplatin, DDP, Paclitaxel, PTX
Chinese Academy of Medical Sciences, Akeso Pharmaceuticals, Inc.
Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
04/24
10/24
NCT06202716: Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Not yet recruiting
2
50
RoW
Cadonilimab plus CapeOX chemotherapy
Nanfang Hospital, Southern Medical University
Gastric Cancer
04/26
04/26
AK104-IIT-041, NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting
2
50
RoW
Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur
Harbin Medical University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/27
03/27
NCT06405490: NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Recruiting
2
30
RoW
Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine, First-Line, Advanced Cancer, Pancreatic Adenocarcinoma, Drug Use
08/26
12/26
NCT06349967: Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Not yet recruiting
2
59
NA
Nab-paclitaxel Combined With Cadonilimab (AK104)
West China Hospital
Gastric Cancer
04/27
05/27
AK104-IIT-C-N1-0104, NCT06426797: Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
25
NA
Cadonilimab plus anlotinib
Peking University People's Hospital, Akeso Pharmaceuticals, Inc.
Locally Advanced Esophageal Squamous Cell Carcinoma
05/25
05/27
NCT06367075: A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Not yet recruiting
2
53
NA
Cadonilimab, AK104, Adriamycin, Doxorubicin
Wuhan Union Hospital, China, Sun Yat-sen University, Xiangya Hospital of Central South University, Yunnan Cancer Hospital, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Guangxi Medical University
Advanced Soft-tissue Sarcoma
03/27
03/29
NCT06367088: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Recruiting
2
27
RoW
Cadonilimab, physician's choice of chemotherapy
Wuhan Union Hospital, China
Triple-negative Breast Cancer, Cadonilimab
04/26
04/27
NCT06406426: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

Recruiting
2
40
RoW
Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
Fudan University
Gastric / Gastroesophageal Junction Adenocarcinoma
05/25
09/26
AK104-IIT-C-S-0010, NCT06327698: Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Not yet recruiting
2
30
NA
Cadonilimab, AK104, anlotinib
Hunan Cancer Hospital
Melanoma
05/26
05/27
AK104-IIT-C-M-0035, NCT06406634: Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
Cadonilimab, AK104, Lenvatinib
Hunan Cancer Hospital
Hepatocellular Carcinoma
04/26
04/27
SCALE, NCT06361758: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Withdrawn
2
30
RoW
Cadonilimab+Lenvatinib
Shanghai Zhongshan Hospital, Sun Yat-sen University, Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
05/26
05/27
NCT05687851: Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Recruiting
2
33
RoW
Cadonilimab(AK104), EBRT, BT
Chongqing University Cancer Hospital, Liaoning Tumor Hospital & Institute, Henan Cancer Hospital, Fujian Cancer Hospital
Locally Advanced Cervical Cancer
12/24
12/26
NCT05833971: Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
43
NA
cadonilimab+chemotherapy, AK104
Guangzhou Institute of Respiratory Disease
Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
06/24
06/26
CBC, NCT05812534: Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Not yet recruiting
2
36
NA
Cadonilimab
Second Affiliated Hospital of Nanchang University, Hunan Cancer Hospital, Fujian Cancer Hospital
Non Small Cell Lung Cancer, Brain Metastases
06/24
06/25
NCT06532539: Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Recruiting
2
30
RoW
Paclitaxel and Cisplatin, TP, Cadonilimab, AK104, Radiotherapy
Shandong Cancer Hospital and Institute
Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
05/25
05/26
AK104-IIT 039, NCT06416930: Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Not yet recruiting
2
59
NA
Cadonilimab Combined with chemotherapy, AK104
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Akesobio
Pleural Mesothelioma
06/27
06/29
NCT05980689: Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Recruiting
2
33
RoW
AK104, Cadonilimab, Capecitabine, Neoadjuvant Radiotherapy
Sun Yat-sen University, Akeso, Haplox Biotechnology Co., Ltd.
Locally Advanced Rectal Cancer
06/24
01/25
NCT06427057: A Study of Cadonilimab(AK104)Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Not yet recruiting
2
40
NA
Cadonilimab plus chemotherapy, Cadonilimab plus TKI
Tongji Hospital
Urinary System Tumor
12/25
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
quavonlimab (MK-1308) / Merck (MSD)
KeyImPaCT, NCT03516981 / 2017-003134-85: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Completed
2
245
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Favezelimab, MK-4280, Lenvatinib, MK-7902, Quavonlimab, MK-1308
Merck Sharp & Dohme LLC
Advanced Non-Small Cell Lung Cancer
06/25
06/25
2019-003956-35: Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 Refractory MEL

Not yet recruiting
1/2
200
Europe
PEMBROLIZUMAB, MK-1308 -process 2 drug product (25 mg/vial), Lenvatinib, MK-3475, MK-1308, E7080/MK-7902, MK-7684, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
MK-1308-001, NCT03179436: Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors

Checkmark Data from MK-1308-001 trial in combination with pembrolizumab in advanced melanoma
Jun 2022 - Jun 2022: Data from MK-1308-001 trial in combination with pembrolizumab in advanced melanoma
Checkmark Data from MK-1308-001 study in combination with quavonlimab for NSCLC
Oct 2020 - Oct 2020: Data from MK-1308-001 study in combination with quavonlimab for NSCLC
Completed
1/2
415
Europe, Canada, Japan, US, RoW
Quavonlimab, MK-1308, Pembrolizumab, Keytruda®, Pembrolizumab/Quavonlimab, MK-1308A
Merck Sharp & Dohme LLC
Advanced Solid Tumors
04/24
04/24
KEYMAKER-U02 Substudy 02A, NCT04305041: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Active, not recruiting
1/2
200
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Quavonlimab, MK-1308, Vibostolimab, MK-7684, Lenvatinib, MK-7902, LENVIMA®, ATRA, VESANOID
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
ebronucimab (AK102) / Akesobio
NCT05255094: A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Completed
3
464
RoW
AK102, Placebo
Akeso
Hyperlipidemia
06/22
06/22
NCT05255458: A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia

Completed
3
122
RoW
AK102, Placebo
Akeso
Hyperlipidemia
01/23
01/23
NCT05260411: A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia

Completed
3
246
RoW
AK102, Placebo
Akeso
Hyperlipidemia
12/22
12/22
NCT06641388: A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects

Not yet recruiting
1
180
RoW
Ebronucimab
Akeso
Healthy Subjects (HS)
04/25
06/25
NCT07043283: A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects

Not yet recruiting
1
204
RoW
Ebronucimab
Akeso
Healthy Subjects
04/26
04/26
Kaitanni (cadonilimab) / Akesobio
ChiCTR2300070963: Prospective, open cohort study of sulfatinib in combination with cadonilimab for first-line treatment of extensive-stage small-cell lung cancer

Not yet recruiting
4
80
 
None ;None ;None ;None
The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, self-finance
Small cell lung cancer
 
 
ChiCTR2200065303: A single-arm, prospective, exploratory clinical study of fruquintinib plus candonilimab in advanced colorectal cancer

Not yet recruiting
4
31
 
fruquintinib plus candonilimab
Nanjing Hospital of Traditional Chinese Medicine; Nanjing Hospital of Traditional Chinese Medicine, Self-financing
colorectal cancer
 
 
ChiCTR2300071201: Exploratory clinical study of candonilimab plus bevacizumab in patients with relapsed diffuse midline glioma

Recruiting
4
30
 
Cardonilizumab combined with bevacizumab was administered every 3 weeks until 1 year or disease progression or unacceptable toxicities, or withdrew consent.
Sanbo Brain Hospital Capital Medical University; Sanbo Brain Hospital Capital Medical University, Akeso Biopharma Co., Ltd.
diffuse midline glioma
 
 
LungCadX, ChiCTR2300071681: A Phase II Clinical Study of Cadonilimab in Combination with Chemotherapy as First-Line Treatment for PD-L1 Negative Advanced Non-Small Cell Lung Cancer

Not yet recruiting
4
54
 
Cadonilimab + chemotherapy (chemotherapy regimen determined by the investigator)
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Shanghai Pulmonary Hospital
Non-Small Cell Lung Cancer
 
 
ChiCTR2400082911: A prospective, single-arm, single-center clinical trial of Cadonilimab combined with radiotherapy in the first-line treatment of advanced malignant melanoma

Not yet recruiting
4
40
 
Cadonilimab combined with radiotherapy
Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Self-funded
advanced malignant melanoma
 
 
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Active, not recruiting
3
610
RoW
AK104, Oxaliplatin, Capecitabine, Placebo
Akeso
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
04/25
10/25
AK104-IIT-C-M-0020, NCT06566755: Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer

Recruiting
3
30
RoW
Cadonilimab (AK104) combined with chemotherapy and bevacizumab
Caigang Liu
Colorectal Cancer
02/26
02/27
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
3
506
RoW
cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo
Akeso
Gastric and Gastroesophageal Junction Adenocarcinoma
11/26
07/27
AK104-308, NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting
3
469
RoW
AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib
Akeso
Hepatocellular Carcinoma
10/25
05/26
NCT06542549: Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer

Not yet recruiting
3
100
NA
AK104
Anhui Provincial Hospital
Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, Safety
10/27
10/30
NCT06664983: TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
84
RoW
TPC chemotherapy, NAB-paclitaxel, cisplatin, and capecitabine, cadonilimab combined TPC chemotherapy, cadonilimab combined NAB-paclitaxel, cisplatin, and capecitabine
Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
10/25
10/26
AK104-309, NCT06617416: A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Recruiting
3
560
RoW
Cadonilimab (AK104), Sugemalimab
Akeso
NSCLC (Non-small Cell Lung Cancer)
10/26
12/28
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Recruiting
3
418
RoW
Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Akeso Pharmaceuticals, Inc.
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
01/25
01/27
AK104-306, NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Recruiting
3
570
RoW
AK104, placebo
Akeso
Hepatocellular Carcinoma
01/26
01/27
NeoCaCRT-III, NCT06832917: Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial

Not yet recruiting
3
238
NA
AK104 plus, Chemo only
Wan He
Rectal Cancer
12/28
12/29
COMPASSION-16, NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Active, not recruiting
3
445
RoW
AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo
Akeso
Cervical Cancer
04/25
12/25
NCT06949033: Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting
3
668
RoW
Neoadjuvant cadonilimab combined with perioperative SOX, Neoadjuvant placebo plus perioperative SOX
Zuoyi Jiao
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR, ORR,OS,PFS
12/28
12/30
NCT07023315: A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Not yet recruiting
3
760
RoW
Cadonilimab, SOX chemotherapy
Akeso
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
07/29
07/31
AK104-307, NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not yet recruiting
3
642
RoW
AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel
Akeso
Locally Advanced or Metastatic NSCLC
08/25
11/26
COMPASSION-18, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer

Active, not recruiting
3
636
RoW
AK104, EBRT, BT, cisplatin, Placebo
Akeso
Locally Advanced Cervical Carcinoma
05/26
05/29
ChiCTR2400087138: A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Recruiting
3
469
 
Cadonilimab(AK104) + Lenvatinib+ Transarterial Chemoembolization (TACE); Placebo for AK104+ Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE); Cadonilimab(AK104) + Placebo for Lenvatinib+ Transarterial Chemoembolization (TACE)
Zhongda Hospital Southeast University; Zhongda Hospital Southeast University, Akeso Pharma Co., Ltd.
Hepatocellular carcinoma
 
 
NCT05941741: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Active, not recruiting
3
380
RoW
Intensity Modulated Radiation Therapy, IMRT, Chemotherapy, Induction chemotherapy, Concurrent chemotherapy, Gemcitabine, Cisplatin, Immune checkpoint inhibitor, Cadonilimab, AK104, PD-1/CTLA-4 inhibitor, Low-dose radiotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
12/26
12/29
NCT06241599: A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Recruiting
2/3
300
RoW
GP/PFLL+AK104, GP/PFLL+placebo
Sun Yat-sen University
Recurrent or Metastatic Nasopharyngeal Carcinoma
02/26
02/29
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting
2/3
90
RoW
Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection
RemeGen Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/26
12/27
ChiCTR2300076761: Efficacy and Safety of Cadonilimab and COX-2 Inhibitor Combined with Oxaliplatin and Capecitabine (XELOX) in Perioperative Therapy for Locally Advanced Resectable Gastric Adenocarcinoma: A Prospective, Single-Center, Randomized Clinical Trial

Recruiting
2/3
80
 
Cardonilizumab and COX-2 inhibitors combined with capecitabine and oxaliplatin (XELOX) applied in the perioperative period; Capecitabine and oxaliplatin (XELOX) applied in the perioperative period
The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital Sun Yat-sen University, Akeso Pharma Co., Ltd
Gastric cancer
 
 
ChiCTR2300072956: A randomized, controlled, double-blind, multicenter phase II clinical study of PD-1/CTLA-4 dual antibody combined with chemoradiotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma

Not yet recruiting
2/3
64
 
cadonilimab + induction chemotherapy + Concurrent chemoradiotherapy ;placebo + induction chemotherapy + Concurrent chemoradiotherapy
Sichuan Cancer Hospital; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project
nasopharyngeal carcinoma
 
 
NCT06728631: Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

Active, not recruiting
2
22
RoW
Candonilimab and ATRA, other treatment or observation
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Oral Cavity Cancer, Premalignant Lesion
12/23
12/26
AK104-209, NCT04728321: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

Completed
2
32
RoW
AK104 lenvatinib, AK104
Akeso, Akeso Pharmaceuticals, Inc.
Hepatocellular Carcinoma
08/22
08/23
NCT04544644: A Study of Combination Therapy in NSCLC

Not yet recruiting
2
30
NA
AK104+anlotinib
Chinese PLA General Hospital
Non-small Cell Lung Cancer
09/22
09/23
ChiCTR2000035993: A phase II study of AK104 (binding kenetics to PD-1 and CTLA-4) in combination with anlotinib in patients with advanced NSCLC

Not yet recruiting
2
30
 
AK104+anlotinib
Chinese PLA General Hospital; Chinese PLA General Hospital, Charity organization
Non-small cell lung cancer
 
 
NCT04556253: AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

Not yet recruiting
2
29
NA
AK104
Peking University
MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
10/22
10/23
COMPASSION-13, NCT04868708: A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Completed
2
50
RoW
AK104, Bevacizumab, Paclitaxel, PTX, Cisplatin or Carboplatin, DDP,CBP
Akeso
Recurrent or Metastatic Cervical Cancer
02/24
02/24
AK104-215, NCT05215067: A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer

Active, not recruiting
2
44
RoW
AK104, Docetaxel
Akeso
Advanced Non-small Cell Lung Cancer
06/25
06/26
AK104-214, NCT05227651: AK104 in Neoadjuvant Treatment of Cervical Cancer

Completed
2
14
RoW
AK104
Akeso
Cervical Cancer
09/24
09/24
NCT05886257: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Withdrawn
2
RoW
Candonilimab, Bevacizumab
Shi Ming
Hepatocellular Carcinoma
03/23
03/23
AK104-216, NCT05319431: A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC

Active, not recruiting
2
60
RoW
AK104, Lenvatinib, TACE
Akeso
Unresectable, Non-metastatic Hepatocellular Carcinoma
08/23
06/25
NCT06383533: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Recruiting
2
28
RoW
Disitamab Vedotin Plus Cadonilimab
Zhejiang Cancer Hospital
Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation
05/25
12/25
GWK2023-001, NCT06335927: HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC

Recruiting
2
45
RoW
HAIC-GEMOX+Cadonilimab+Regorafenib
Fudan University
Intrahepatic Cholangiocarcinoma
05/25
05/26
NCT06341660: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
30
RoW
cadonilimab
Guangzhou Institute of Respiratory Disease
Non-small Cell Lung Cancer
06/25
07/25
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Recruiting
2
40
RoW
Fruquintinib, Cadonilimab, SBRT
Huazhong University of Science and Technology
Colorectal Cancer
02/26
02/27
LungCadX, NCT06424821: Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Recruiting
2
54
RoW
Cadonilimab, Cadonilimab group
Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
09/24
09/25
AK104-RC48 UC 01, NCT06178601: A Study of RC48-ADC Combined With Cadonilimab(AK104)in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
2
36
RoW
RC48-ADC, AK104
Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Urothelial Carcinoma
09/24
04/26
NCT06331650: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Recruiting
2
30
RoW
cadonilimab
Guangzhou Institute of Respiratory Disease
Non-small Cell Lung Cancer
08/25
10/25
NCT06209294: Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Recruiting
2
30
RoW
AK104, Carboplatin, Nab paclitaxel
Xiaohua Wu
Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery
12/25
12/28
NCT06138496: Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Recruiting
2
43
RoW
Cadonilimab Combined With Lenvatinib
Sun Yat-sen University
Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
08/25
12/25
NCT06455046: Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Recruiting
2
37
RoW
AK104, Cadonilimab, Recombinant Human Adenovirus 5 Injection, Recombinant Human Adenovirus Type 5 Injection
Fujian Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province
Cervical Cancer Recurrent
10/25
10/25
AK104-SCLC-01, NCT06406673: A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Recruiting
2
70
RoW
Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib
Henan Cancer Hospital
Extensive Small Cell Lung Cancer
08/24
12/24
NCT06154538: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Recruiting
2
170
RoW
Cadonilimab, 1, FOLFOX regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Colorectal Carcinoma
11/26
11/28
ZF2023-252, NCT06277674: Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Recruiting
2
20
RoW
Cadonilimab plus Pemetrexed and Anlotinib, ICIs in combination with chemotherapy and antiangiogenic therapy
Guangzhou University of Traditional Chinese Medicine, Akeso Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
12/24
06/25
NCT05594914: AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
47
NA
AK104
The First Affiliated Hospital of University of South China
Esophageal Squamous Cell Carcinoma
12/23
12/25
NCT05781958: Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC

Active, not recruiting
2
64
RoW
Cadonilimab+Gem/Cis
Shen Feng
Intrahepatic Cholangiocarcinoma
12/23
12/24
AK104-IIT-003, NCT05430906: AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Recruiting
2
40
RoW
AK104 - Chemotherapy
Hunan Cancer Hospital
Ovarian Cancer
12/23
01/26
CCGLC-011, NCT06187961: Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting
2
36
RoW
HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Lenvatinib plus cadonilimab, levima plus cadonilimab
Tongji Hospital, Akesobio
Hepatocellular Carcinoma Non-resectable
12/25
06/27
NCT06153368: Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

Not yet recruiting
2
30
RoW
Cadonilimab+mFOLFIRINOX, Cadonilimab+Oxaliplatin+ Irinotecan+ Leucovorin+ 5-fluorouracil
The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer
11/24
11/25
MSI-H/dMMR, NCT05913570: Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III Colorectal Cancer

Not yet recruiting
2
22
RoW
Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody, Neoadjuvant therapy with Cadonilimab
LiuYing
Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
12/23
12/23
ChiCTR2200067057: Cadonilimab in combination with TPC chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patient who failed to prior immunotherapy: a prospective, open labeled phase II clinical trial

Completed
2
25
 
cadonilimab in combination with TPC chemotherapy
Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, NA
Nasopharyngeal Carcinoma
 
 
NCT05760599: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Recruiting
2
30
RoW
Candonilimab, Bevacizumab
Shi Ming
Hepatocellular Carcinoma
01/24
07/24
NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

Recruiting
2
53
RoW
Cadonilimab + bevacizumab + FOLFOX
Fudan University
Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab
12/25
12/26
CATPCC-01, NCT06511726: Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Recruiting
2
29
RoW
Cadonilimab, AK-104
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Cancer
10/25
10/27
NCT06793813: Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
44
RoW
cadonilimab,bevacizumab,docetaxel
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Stage IVB Lung Cancer, Non-Squamous
12/25
12/26
AK104-IIT-042, NCT06196775: A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2
36
RoW
AK104+AK112
Harbin Medical University
Hepatocellular Carcinoma
01/26
01/27
NCT05926700: Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Recruiting
2
27
RoW
Candonilimab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Soft Tissue Sarcoma
08/24
01/25
AK104-IIT-007, NCT06202313: Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Not yet recruiting
2
128
RoW
Cadonilimab, AK104, Eribulin
Shengjing Hospital
Triple Negative Breast Cancer
12/25
12/28
NCT06251388: A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab(AK104) for Newly Diagnosed Local Advanced Cervical Cancer

Recruiting
2
50
RoW
AK104, Cadonilimab Injection
West China Second University Hospital, Affiliated Hospital of North Sichuan Medical College, The Affiliated Hospital Of Southwest Medical University
Cervical Cancer
05/25
10/26
AK104-IIT-005, NCT05377658: AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Recruiting
2
43
RoW
AK104, Cadonilimab, Albumin-Bound Paclitaxel, Carboplatin
Henan Cancer Hospital
Non-small Cell Lung Cancer
12/24
12/27
NCT05947201: Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
26
RoW
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil, rutine
Weijia Fang, MD, Akeso Pharmaceuticals, Inc.
The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC
03/24
10/24
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting
2
20
RoW
cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU
Fujian Cancer Hospital
Colorectal Cancer
03/24
03/25
NCT06310473: Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Not yet recruiting
2
30
RoW
Cadonilimab, AK104, Oxaliplatin, Capecitabine
Nanfang Hospital, Southern Medical University
Gastric Cancer, Esophagogastric Junction Cancer
03/25
03/28
NCT06467500: A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy

Recruiting
2
48
RoW
Cadonilimab (AK104)
Xin-Hua Xu
Non-small Cell Lung Cancer
12/26
12/26
EC-CRT-006, NCT06143748: Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer

Recruiting
2
46
RoW
Cadonilimab, AK104, Paclitaxel and cisplatin, taxol, DDP, intensity-modulated radiotherapy, IMRT
Sun Yat-sen University
Esophagus Cancer
12/25
12/27
NCT06215651: Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
Cadonilimab lenvatinib, AK104
Peking Union Medical College Hospital
Cadonilimab and Lenvatinib
01/25
01/27
NCT06280105: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Recruiting
2
40
RoW
Cadonilimab+regorafenib
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Hepatocellular Carcinoma
03/26
03/27
AK104-IIT-014, NCT05522894: AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Not yet recruiting
2
80
NA
AK104, Cadonilimab, Cisplatin, DDP, Paclitaxel, PTX
Chinese Academy of Medical Sciences, Akeso Pharmaceuticals, Inc.
Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
04/24
10/24
NCT06202716: Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Not yet recruiting
2
50
RoW
Cadonilimab plus CapeOX chemotherapy
Nanfang Hospital, Southern Medical University
Gastric Cancer
04/26
04/26
AK104-IIT-041, NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Recruiting
2
50
RoW
Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur
Harbin Medical University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/27
03/27
NCT06405490: NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Recruiting
2
30
RoW
Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine, First-Line, Advanced Cancer, Pancreatic Adenocarcinoma, Drug Use
08/26
12/26
NCT06349967: Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

Not yet recruiting
2
59
NA
Nab-paclitaxel Combined With Cadonilimab (AK104)
West China Hospital
Gastric Cancer
04/27
05/27
AK104-IIT-C-N1-0104, NCT06426797: Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
25
NA
Cadonilimab plus anlotinib
Peking University People's Hospital, Akeso Pharmaceuticals, Inc.
Locally Advanced Esophageal Squamous Cell Carcinoma
05/25
05/27
NCT06367075: A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Not yet recruiting
2
53
NA
Cadonilimab, AK104, Adriamycin, Doxorubicin
Wuhan Union Hospital, China, Sun Yat-sen University, Xiangya Hospital of Central South University, Yunnan Cancer Hospital, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Guangxi Medical University
Advanced Soft-tissue Sarcoma
03/27
03/29
NCT06367088: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Recruiting
2
27
RoW
Cadonilimab, physician's choice of chemotherapy
Wuhan Union Hospital, China
Triple-negative Breast Cancer, Cadonilimab
04/26
04/27
NCT06406426: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

Recruiting
2
40
RoW
Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
Fudan University
Gastric / Gastroesophageal Junction Adenocarcinoma
05/25
09/26
AK104-IIT-C-S-0010, NCT06327698: Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Not yet recruiting
2
30
NA
Cadonilimab, AK104, anlotinib
Hunan Cancer Hospital
Melanoma
05/26
05/27
AK104-IIT-C-M-0035, NCT06406634: Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Recruiting
2
30
RoW
Cadonilimab, AK104, Lenvatinib
Hunan Cancer Hospital
Hepatocellular Carcinoma
04/26
04/27
SCALE, NCT06361758: Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Withdrawn
2
30
RoW
Cadonilimab+Lenvatinib
Shanghai Zhongshan Hospital, Sun Yat-sen University, Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
05/26
05/27
NCT05687851: Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Recruiting
2
33
RoW
Cadonilimab(AK104), EBRT, BT
Chongqing University Cancer Hospital, Liaoning Tumor Hospital & Institute, Henan Cancer Hospital, Fujian Cancer Hospital
Locally Advanced Cervical Cancer
12/24
12/26
NCT05833971: Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Not yet recruiting
2
43
NA
cadonilimab+chemotherapy, AK104
Guangzhou Institute of Respiratory Disease
Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
06/24
06/26
CBC, NCT05812534: Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases

Not yet recruiting
2
36
NA
Cadonilimab
Second Affiliated Hospital of Nanchang University, Hunan Cancer Hospital, Fujian Cancer Hospital
Non Small Cell Lung Cancer, Brain Metastases
06/24
06/25
NCT06532539: Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Recruiting
2
30
RoW
Paclitaxel and Cisplatin, TP, Cadonilimab, AK104, Radiotherapy
Shandong Cancer Hospital and Institute
Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
05/25
05/26
AK104-IIT 039, NCT06416930: Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Not yet recruiting
2
59
NA
Cadonilimab Combined with chemotherapy, AK104
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Akesobio
Pleural Mesothelioma
06/27
06/29
NCT05980689: Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Recruiting
2
33
RoW
AK104, Cadonilimab, Capecitabine, Neoadjuvant Radiotherapy
Sun Yat-sen University, Akeso, Haplox Biotechnology Co., Ltd.
Locally Advanced Rectal Cancer
06/24
01/25
NCT06427057: A Study of Cadonilimab(AK104)Combined With Standard Treatment for Function Preservation in Urinary System Tumors

Not yet recruiting
2
40
NA
Cadonilimab plus chemotherapy, Cadonilimab plus TKI
Tongji Hospital
Urinary System Tumor
12/25
12/27
 

Download Options